FDA has not approved the Lysine drug against COVID-19 as it is listed as a misbranded product that infringes the Federal Food, Drug, and Cosmetic Act.
On December 21, 2020, FDA issued a warning letter claiming that Flu Immune Drops, L-Lysine, Lysine Extra, and Monolaurin are unapproved and misbranded drugs sold in violation of ''section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a).'' Furthermore, delivery of these products into interstate commerce is prohibited under ''sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).''
Even PubMed noted that providing additional micronutrients or conditional amino acids may impact COVID-19-related outcomes is uncertain and lacking scientific evidence.
Therefore, we conclude that the Lysine drug is not recommended against COVID-19 by health agencies like the World Health Organization, including the FDA, so the claim is false.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19, including symptoms, prevention, and available treatment, please refer to the World Health Organization or your national healthcare authority.